Theranexus Exeltis (Insud Pharma) announce an agreement licence for marketing of Theranexus TX01 in the treatment of two rare neurological diseases

17 déc. 2024

Theranexus strikes a major milestone as IRIS steps in with a strategic licensing and distribution deal to propel TX01 toward global commercialization in rare neurological diseases.

Lyon, France, dec 17, 2024 – Theranexus, an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, and Exeltis, a global pharmaceutical company of the Insud Pharma group, announce the signing of a licensing and distribution agreement for the commercialization of Theranexus’ TX01, a new formulation of a compound already approved for the treatment of rare neurological diseases.

Download Press Release in French